In this report, NIH and other U.S. Government agencies describe accomplishments in the first year of the National Action Plan for Combating Multidrug-Resistant Tuberculosis (MDR-TB). Read the year one report.
National Action Plan for Combating Multidrug-Resistant Tuberculosis: Six–Month Progress Report and Future Direction
In this report, NIH and other U.S. Government agencies describe progress toward achieving the goals of the National Action Plan for Combating Multidrug-Resistant Tuberculosis (MDR-TB). Read the six-month progress report.
In understanding TB, it’s important to understand the difference between Mtb infection and TB disease Mtb Infection and TB disease, as well as understand multidrug-resistant tuberculosis (MDR TB) and extensively drug-resistant tuberculosis (XDR TB). Read about tuberculosis (TB) infection, disease and drug resistance
An NIAID study suggests that the increased frequency of an immune cell called CD14++CD16- monocyte is a strong indicator that a patient with HIV and tuberculosis (TB) may develop complications from anti-HIV drugs. For unclear reasons, a subset of people with both HIV and TB experience worsening of their TB symptoms after starting antiretroviral therapy (ART) to treat HIV. The study, which appears in the October 2, 2014, issue of PLOS Pathogens, offers a better understanding of why this may occur. Read about the marker that predicts tuberculosis complications in HIV patients.
To prepare this research agenda focused specifically on MDR/XDR TB, NIAID consulted U.S. and international TB experts, academia, activist groups, and other government agencies. While it concentrates on only a portion of the scientific challenges associated with TB, this agenda identifies high-priority research needs that complement the robust basic research and product development program NIAID supports for TB in general. Read the multidrug-resistant and extensively drug-resistant tuberculosis research agenda.
NIAID supports research to elucidate the mechanisms of drug resistance, identify new TB drug targets and candidate drugs, and evaluate novel TB drugs and optimal drug combinations in preclinical and clinical studies. View a series of illustrations that demonstrate the mechanism of TB drugs.